Cargando…
Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction
Autores principales: | Zheng, Yun-zhe, Liu, Zhao-yuan, Li, Yue, Lv, Xiao-ying, Wu, Yi, Huang, Meng-wen, Pan, Xing-chao, Chen, Jian-feng, Lin, Chang-dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028314/ https://www.ncbi.nlm.nih.gov/pubmed/36944800 http://dx.doi.org/10.1038/s41401-023-01071-0 |
Ejemplares similares
-
A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022) -
Structures of ACE2–SIT1 recognized by Omicron variants of SARS-CoV-2
por: Shen, Yaping, et al.
Publicado: (2022) -
Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein–ACE2 interaction
por: Yuan, MengYa, et al.
Publicado: (2021) -
Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
por: Lin, ChangDong, et al.
Publicado: (2021) -
Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
por: Lin, ChangDong, et al.
Publicado: (2021)